Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002131
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Pilot Study of OPC-8212 Vesnarinone in Persons With AIDS-Related Kaposis Sarcoma
Sponsor:
Otsuka America Pharmaceutical
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Pilot Study of OPC-8212 Vesnarinone in Persons With AIDS-Related Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
1996-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposis sarcoma
Detailed Description:
Twenty-eight patients 14 per cohort receive daily vesnarinone at one of two doses At least seven patients at the lower dose must have completed 2 weeks of therapy before subsequent patients are entered at the higher dose Patients who successfully complete 16 weeks of treatment may receive maintenance therapy for the duration of the study approximately 12-18 months
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 22-93-254 | None | None | None |